

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4739669

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CHANG HEE MIN	08/06/2015
YONG EUN KIM	08/06/2015
BYUNG KYU OH	08/02/2015
JI SUN LEE	08/03/2015
HYE JIN HEO	08/03/2015
JU HOON OH	08/03/2015
WOONG CHO	08/03/2015
RECEIVING PARTY DATA	
Name:	HANALL BIOPHARMA CO., LTD.
Street Address:	43, SANGSEODANG 1-GIL
Internal Address:	DAEDEOK-GU
City:	DAEJEON
State/Country:	KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF
Postal Code:	306-120
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15841971
CORRESPONDENCE DATA	
Fax Number:	(617)428-7045
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6174280200
Email:	patentadministrator@clarkelbing.com
Correspondent Name:	KAREN L. ELBING
Address Line 1:	CLARK & ELBING LLP
Address Line 2:	101 FEDERAL STREET, 15TH FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	51230-011004
NAME OF SUBMITTER:	KAREN L. ELBING
SIGNATURE:	/Karen L. Elbing/

PATENT

DATE SIGNED:	12/18/2017
Total Attachments: 9 source=Assignment - Inventors to Hanall Biopharma#page1.tif source=Assignment - Inventors to Hanall Biopharma#page2.tif source=Assignment - Inventors to Hanall Biopharma#page3.tif source=Assignment - Inventors to Hanall Biopharma#page4.tif source=Assignment - Inventors to Hanall Biopharma#page5.tif source=Assignment - Inventors to Hanall Biopharma#page6.tif source=Assignment - Inventors to Hanall Biopharma#page7.tif source=Assignment - Inventors to Hanall Biopharma#page8.tif source=Assignment - Inventors to Hanall Biopharma#page9.tif	

ASSIGNMENT

WHEREAS, the undersigned inventor(s) (referred to, collectively, if more than one, as "Assignor") have made an invention entitled NI-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME for which an application for United States Letters Patent was filed on August 6, 2015 as Application Serial No. 14/766,203, and

WHEREAS, **HANALL BIOPHARMA CO., LTD.** ("Assignee") having a place of business at **43, Sangseodang 1-gil, Daedeok-gu, Daejeon 306-120 Republic of Korea**, desires to acquire all right, title and interest in and to the above identified invention and application;

NOW, THEREFORE, Assignor, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, does hereby sell, assign, convey and transfer unto Assignee all right, title and interest in and to the above identified invention and application, together with all corresponding international and foreign applications and patents which may be filed thereon, including the right to claim priority from the above identified United States application; and Assignor hereby agrees that Assignor will sign all lawful papers, including, without limitation, all divisional, continuation, renewal, extension and reissue applications, and make all rightful oaths in execution thereof, and will generally do everything possible to aid Assignee, its successors, assigns and nominees to obtain and enforce proper protection for the invention in all countries, this obligation to be binding upon Assignor (each and severally, if more than one) and upon Assignor's personal representative or other legal successor.

Assignor hereby authorizes and requests Swanson and Bratschun, L.L.C. to insert herein above the application serial number and filing date of said application when known.

IN TESTIMONY WHEREOF, the undersigned Assignor (and each of them, if more than one) has signed below.

Date:

08/06/2015

Address:

Chang Hee MIN

105-1202, 50, Hallimmal-gil,
Seongdong-gu, Seoul 133-765 Republic of
Korea

Date:

08/06/2015

Address:

Kim yong Eun

Yong Eun KIM

84, Bomunsan-ro, Jung-gu, Daejeon
301-819 Republic of Korea

ASSIGNMENT

WHEREAS, the undersigned inventor(s) (referred to, collectively, if more than one, as "Assignor") have made an invention entitled N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME for which an application for United States Letters Patent was filed on August 6, 2015 as Application Serial No. 14/766,203, and


WHEREAS, **HANALL BIOPHARMA CO., LTD.** ("Assignee") having a place of business at **43, Sangseodang 1-gil, Daedeok-gu, Daejeon 306-120 Republic of Korea**, desires to acquire all right, title and interest in and to the above identified invention and application;

NOW, THEREFORE, Assignor, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, does hereby sell, assign, convey and transfer unto Assignee all right, title and interest in and to the above identified invention and application, together with all corresponding international and foreign applications and patents which may be filed thereon, including the right to claim priority from the above identified United States application; and Assignor hereby agrees that Assignor will sign all lawful papers, including, without limitation, all divisional, continuation, renewal, extension and reissue applications, and make all rightful oaths in execution thereof, and will generally do everything possible to aid Assignee, its successors, assigns and nominees to obtain and enforce proper protection for the invention in all countries, this obligation to be binding upon Assignor (each and severally, if more than one) and upon Assignor's personal representative or other legal successor.

Assignor hereby authorizes and requests Swanson and Bratschun, L.L.C. to insert herein above the application serial number and filing date of said application when known.

IN TESTIMONY WHEREOF, the undersigned Assignor (and each of them, if more than one) has signed below.

Date: 8/02 / 2015
Address:



Byung Kyu OH
413, 5, Seogeumam 3-gil, Gyeryong-si,
Chungcheongnam-do 321-900 Republic of
Korea

Date: _____
Address:

Ji Sun LEE
113-802, 6, Baeul 2-ro, Yuseong-gu,
Daejeon 305-741 Republic of Korea

Date: _____
Address:

Hye Jin HEO
302, 34-2, Gwandeul 4-gil, Yuseong-gu,
Daejeon 305-509 Republic of Korea

Date: _____
Address:

Ju Hoon OH
202-202, 25, Noganim-gil,
Gangneung-si, Gangwon-do 210-932
Republic of Korea

ASSIGNMENT

WHEREAS, the undersigned inventor(s) (referred to, collectively, if more than one, as "Assignor") have made an invention entitled N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME for which an application for United States Letters Patent was filed on August 6, 2015 as Application Serial No. 14/766,203, and

WHEREAS, **HANALL BIOPHARMA CO., LTD.** ("Assignee") having a place of business at **43, Sangseodang 1-gil, Daedeok-gu, Daejeon 306-120 Republic of Korea**, desires to acquire all right, title and interest in and to the above identified invention and application;

NOW, THEREFORE, Assignor, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, does hereby sell, assign, convey and transfer unto Assignee all right, title and interest in and to the above identified invention and application, together with all corresponding international and foreign applications and patents which may be filed thereon, including the right to claim priority from the above identified United States application; and Assignor hereby agrees that Assignor will sign all lawful papers, including, without limitation, all divisional, continuation, renewal, extension and reissue applications, and make all rightful oaths in execution thereof, and will generally do everything possible to aid Assignee, its successors, assigns and nominees to obtain and enforce proper protection for the invention in all countries, this obligation to be binding upon Assignor (each and severally, if more than one) and upon Assignor's personal representative or other legal successor.

Assignor hereby authorizes and requests Swanson and Bratschun, L.L.C. to insert herein above the application serial number and filing date of said application when known.

IN TESTIMONY WHEREOF, the undersigned Assignor (and each of them, if more than one) has signed below.

Date: _____ Address: _____
Byung Kyu OH
413, 5, Seogeumam 3-gil, Gyeryong-si,
Chungcheongnam-do 321-900 Republic of
Korea

Date: 2015. 8. 3 Address: _____
Ji Sun LEE
113-802, 6, Baeul 2-ro, Yuseong-gu,
Daejeon 305-741 Republic of Korea

Date: 2015. 8. 3 Address: _____
Hye Jin HEO
302, 34-2, Gwandeul 4-gil, Yuseong-gu,
Daejeon 305-509 Republic of Korea

Date: _____ Address: _____
Ju Hoon OH
202-202, 25, Noganinam-gil,
Gangneung-si, Gangwon-do 210-932
Republic of Korea

ASSIGNMENT

WHEREAS, the undersigned inventor(s) (referred to, collectively, if more than one, as "Assignor") have made an invention entitled N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME for which an application for United States Letters Patent was filed on August 6, 2015 as Application Serial No. 14/766,203, and

WHEREAS, **HANALL BIOPHARMA CO., LTD.** ("Assignee") having a place of business at **43, Sangseodang 1-gil, Daedeok-gu, Daejeon 306-120 Republic of Korea**, desires to acquire all right, title and interest in and to the above identified invention and application;

NOW, THEREFORE, Assignor, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, does hereby sell, assign, convey and transfer unto Assignee all right, title and interest in and to the above identified invention and application, together with all corresponding international and foreign applications and patents which may be filed thereon, including the right to claim priority from the above identified United States application; and Assignor hereby agrees that Assignor will sign all lawful papers, including, without limitation, all divisional, continuation, renewal, extension and reissue applications, and make all rightful oaths in execution thereof, and will generally do everything possible to aid Assignee, its successors, assigns and nominees to obtain and enforce proper protection for the invention in all countries, this obligation to be binding upon Assignor (each and severally, if more than one) and upon Assignor's personal representative or other legal successor.

Assignor hereby authorizes and requests Swanson and Bratschun, L.L.C. to insert herein above the application serial number and filing date of said application when known.

IN TESTIMONY WHEREOF, the undersigned Assignor (and each of them, if more than one) has signed below.

Date: _____
Address: _____

Byung Kyu OH
413, 5, Seogeumam 3-gil, Gyeryong-si,
Chungcheongnam-do 321-900 Republic of
Korea


Date: _____
Address: _____

Ji Sun LEE
113-802, 6, Baeul 2-ro, Yuseong-gu,
Daejeon 305-741 Republic of Korea

Date: _____
Address: _____

Hye Jin HEO
302, 34-2, Gwandeul 4-gil, Yuseong-gu,
Daejeon 305-509 Republic of Korea

Date: 2015. 8. 3
Address: _____


Ju Hoon OH
202-202, 25, Noganinam-gil,
Gangneung-si, Gangwon-do 210-932
Republic of Korea

ASSIGNMENT

WHEREAS, the undersigned inventor(s) (referred to, collectively, if more than one, as "Assignor") have made an invention entitled N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME for which an application for United States Letters Patent was filed on August 6, 2015 as Application Serial No. 14/766,203, and

WHEREAS, **HANALL BIOPHARMA CO., LTD.** ("Assignee") having a place of business at **43, Sangseodang 1-gil, Daedeok-gu, Daejeon 306-120 Republic of Korea**, desires to acquire all right, title and interest in and to the above identified invention and application;


NOW, THEREFORE, Assignor, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, does hereby sell, assign, convey and transfer unto Assignee all right, title and interest in and to the above identified invention and application, together with all corresponding international and foreign applications and patents which may be filed thereon, including the right to claim priority from the above identified United States application; and Assignor hereby agrees that Assignor will sign all lawful papers, including, without limitation, all divisional, continuation, renewal, extension and reissue applications, and make all rightful oaths in execution thereof, and will generally do everything possible to aid Assignee, its successors, assigns and nominees to obtain and enforce proper protection for the invention in all countries, this obligation to be binding upon Assignor (each and severally, if more than one) and upon Assignor's personal representative or other legal successor.

Assignor hereby authorizes and requests Swanson and Bratschun, L.L.C. to insert herein above the application serial number and filing date of said application when known.

IN TESTIMONY WHEREOF, the undersigned Assignor (and each of them, if more than one) has signed below.

Date: 2015. 08. 03.

Address:



Woong CHO
302, 58, Gwandeul 4-gil, Yuseong-gu,
Daejeon 305-509 Republic of Korea